 |
Understanding the Scientific Principles Behind TNF Failure and Cycling CME/CE Author Information and Disclosures Release Date: May 30, 2008; Valid for credit through May 30, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.5 contact hours are in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity- Understanding the Scientific Principles Behind TNF Failure and CyclingAllan Gibofsky, MD, JD, FACP, FCLM; Joseph A. Markenson, MD; Stephen A. Paget, MD, FACP, FACRAvailable As: Slides/Video | Slides/Transcript
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review the current understanding on the pathophysiology of rheumatoid diseases
- Review pharmacologic strategies for the treatment of rheumatoid arthritis (RA) as it relates to the mechanism of action of therapeutic interventions
- Discuss the potential reasons for loss of treatment effect to a biologic agent
- Evaluate current treatments and their limitations as they relate to the management of RA disease and its systemic manifestations
Authors and Disclosures Allan Gibofsky, MD
Disclosure: Allan Gibofsky, MD, JD, has disclosed that he owns
stock, stock options, or bonds in Abbott, Amgen, Bristol-Myers Squibb, and Johnson & Johnson. Dr. Gibofsky has also disclosed that he has served as an advisor or consultant to, and on the speaker's bureau for, Abbott, Amgen, Bristol-Myers Squibb, and Wyeth. Joseph A. Markenson, MD
Disclosure: Joseph A. Markenson, MD, has disclosed that he has received grants for educational activities from Amgen/Wyeth, Abbott,
and Bristol-Myers Squibb. Dr. Markenson has also disclosed that he has served as an advisor or consultant to Amgen/Wyeth and Abbott. Stephen A. Paget, MD
Disclosure: Stephen A. Paget, MD, has disclosed that he has served as a consultant for Pfizer, Abbott, Genentech, and Pfizer. Dr. Paget has also disclosed that he has served as chair of the Data Safety and Monitoring Board of Medarex.
Helen Fosam, PhD
Disclosure: Helen Fosam, PhD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
